Grand River Aseptic Manufacturing announces first planned investment in capacity expansion.
Grand River Aseptic Manufacturing, Inc. (GRAM) announced on March 6, 2018 the addition of syringe filling capabilities at its FDA-inspected, cGMP-compliant manufacturing facility in Grand Rapids, MI. A Colanar FSV syringe filler, which can also handle cartridges, will use the existing single-use systems for small-molecule APIs and biologics projects. The equipment will be qualified and operational by the second quarter of 2018.
The capital investments were made following the announcement of a partnership deal with Arlington Capital Partners, a private equity firm. “With the support of Arlington, GRAM intends to invest heavily in building out our capabilities in the next couple of years with state-of-the-art equipment and a new facility. The new syringe filler is the first of many exciting announcements we will be making this year,” said Tom Ross, president and CEO of GRAM, in a press release.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.